Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744741 · ClinicalTrials.gov registry record
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
A clinical trial, sponsored by Inflammatix.
- Completed
- Registry status
- 585
- Enrollment target
NCT03744741 is a clinical trial that has completed, run by Inflammatix. The registered enrollment target is 585 participants.
The verdict
NCT03744741 has completed, sponsored by Inflammatix.
- COMPLETED
- Registry status
- 585 participants
- Enrollment target
Study Summary
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant prognosis and gene expression results in the HostDx Sepsis test will be validated. Participants presenting to the emergency departments of enrolling sites with a suspected infection and 1 vital signs OR suspected sepsis and 2 vital sign changes as stated in the protocol are meeting enrollment criteria
Interventions
- DIAGNOSTIC_TEST HostDx Sepsis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 585 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2020-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03744741
The ClinicalTrials.gov registry entry for NCT03744741 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 585 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inflammatix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HostDx Sepsis is the first listed.
NCT03744741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03744741 about?
NCT03744741 is a clinical study titled "HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study". This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant pro...
What is the current status of trial NCT03744741?
This trial is currently completed. The enrollment target is 585 participants. The study started on 2018-07-23. Estimated completion is 2020-01-20.
What interventions are being tested in trial NCT03744741?
The interventions under investigation include: HostDx Sepsis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03744741?
This trial is sponsored by Inflammatix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.